Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia

Haemophilia

Volumn 8, Issue 6, 2002, Pages 768-775

  Grunewald M ^a   Siegemund, A ^b   Grunewald A ^a   Konegen, A ^a   Koksch, M ^b   Griesshammer, M ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTHROPATHY; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR DEFICIENCY; BODY WEIGHT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE PREDISPOSITION; DOWN REGULATION; FIBRINOLYSIS; HEMOPHILIA; HEMOSTASIS; HUMAN; HYPOTHESIS; INJURY; MALE; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PRIORITY JOURNAL;

EID: 0036860471     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00686.x     Document Type: Article

References (32)

1. Jones P. Haemophilia: a global challenge. Haemophilia 1995; 1: 11-3.
2. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
3. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. Thromb Haemost 2000; 84: 977-80.
4. Walsh PN, Rainsford SG, Biggs R. Platelet coagulant activities and clinical severity in hemophilia. Thromb Diath Haemorrh 1973; 29: 722-9.
5. Tuddenham EG, Schwaab R, Seehafer J et al. Haemophilia A database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, 2nd edn. Nucleic Acids Res 1994 22: 4851-68.
6. Nichols WC, Amano K, Cacheris PM et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-7.
7. van't Veer C, Golden NJ, Kalafatis M et al. An in vitro analysis of the combination of hemophilia A and factor V Leiden. Blood 1997; 90: 3067-72.
8. Lee DH, Walker IR, Teitel J et al. Effect of the factor V Leiden mutation on the clinical expression of severe haemophilia A. Thromb Haemost 2000; 83: 387-91.
9. Ettinghausen BE, Halimeh S, Kurnik K et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-20.
10. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among 'severe' hemophiliacs with a 'milder' bleeding diathesis. Thromb Haemost 1995; 74: 1255-8.
11. Gaffney PJ, Edgell TA, Whitton CM. The haemostatic balance - Astrup revisited. Haemostasis 1999; 29: 58-71.
12. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60.
13. Golubeva M, Grigor'eva M, Jakunina L et al. The state of the fibrinolytic system in haemophiliacs. Haemophilia 2000; 6: 203.
14. Al-Mondhiry H. Platelet release in hemophilia. Thromb Haemost 1987; 57: 294-7.
15. White GC 2nd, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Factor VIII and Factor IX Subcommittee. Thromb Haemost 2001; 85: 560.
16. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
17. Hemker HC, Wielders S, Kessels H et al. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
18. Hemker HC, Giesen PL, Ramjee M et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-91.
19. Baglia FA, Walsh PN. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J Biol Chem 2000; 275: 20514-9.
20. von dem Borne PA, Bajzar L, Meijers JC et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
21. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
22. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
23. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10: 111-3.
24. Chandler WL, Alessi MC, Aillaud MF et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96: 761-8.
25. Chandler WL, Alessi MC, Aillaud MF et al. Formation, inhibition and clearance of plasmin in vivo. Haemostasis 2000; 30: 204-18.
26. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995; 8: 277-90.
27. Nesheim M, Wang W, Boffa M et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
28. Chetaille P, Alessi MC, Kouassi D et al. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-5.
29. Antovic J, Schulman S, Eelde A et al. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia 2001; 7: 557-60.
30. Mosnier LO, Lisman T, van den Berg HM et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035-9.
31. Mosnier LO, dem Borne PA, Meijers JC et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
32. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.